RecruitingNot applicableNCT07187947
Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway
Studying NON RARE IN EUROPE: Gender dysphoria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Principal Investigator
- Maria Cristina Meriggiola, MD, PhD
- Intervention
- Feminizing GAHT(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2035
Study locations (1)
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, BO, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07187947 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Gender dysphoria
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07252687The Effect of Gender-affirmative Measures on Breast Perception in Trans MenMedical University Innsbruck
- RECRUITINGNCT07286123Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)University Hospitals Cleveland Medical Center
- RECRUITINGNCT06670053Puberty, Testosterone, and Brain DevelopmentUniversity of Colorado, Denver
- RECRUITINGNCT05318755China Gender-affirming Hormone Therapy StudyPeking University Third Hospital
- RECRUITINGPHASE3NCT04979338Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming SurgeriesCedars-Sinai Medical Center